Relating to the establishment of a grant program to fund the United States Food and Drug Administration's drug development trials with ibogaine for the purpose of securing the administration's approval as a medication for treatment of opioid use disorder, co-occurring substance use disorder, and any other neurological or mental health conditions for which ibogaine demonstrates efficacy.
HB 3717 would create a new grant program within the Health and Human Services Commission to help fund FDA drug-development trials for ibogaine, with the goal of obtaining federal approval for ibogaine as a treatment for opioid use disorder, co-occurring substance use disorder, and potentially other neurological or mental health conditions where the drug shows efficacy. The bill directs HHSC to administer the program, adopt rules, solicit applications, and select a grantee through a committee made up of subject-matter experts, philanthropic partners, and legislative designees.
To qualify, applicants must be capable of conducting the trials, seeking FDA approval, and continuing future development work. The application requirements are extensive and include trial design, participant recruitment, cardiac safety protocols, aftercare, data integrity, provider training, plans for Texas-based research and commercialization, and strategies for securing coverage from private insurers, Medicare, Medicaid, TRICARE, and access for uninsured patients. The bill also requires the selected applicant to file an investigational new drug application and seek breakthrough therapy designation, and it contemplates trial sites with cardiac intensive care capabilities and oversight by a Texas-based institutional review board.
The bill would add Chapter 491 to the Health and Safety Code and give HHSC new authority to create and run a state grant program for ibogaine research and development. It would allow the commission to use appropriated funds as well as gifts, grants, and donations, and it requires a selected applicant to match state funding dollar-for-dollar. The measure also seeks to position Texas to retain a commercial interest in patentable intellectual property arising from the trials and to build in-state research, manufacturing, and distribution capacity. Because implementation may depend on federal approvals or waivers, the bill includes a delay mechanism if federal authorization is needed.
The bill appears generally supportive and innovation-oriented, reflecting interest in expanding treatment options for opioid use disorder and related conditions. Its structure suggests a strong policy push to accelerate clinical development while also building safeguards around safety, oversight, and commercialization. The lack of recorded votes or committee transcript excerpts limits the ability to identify detailed public debate, but the bill’s placement in the Public Health committees indicates it was considered primarily as a health and treatment policy measure.
Likely points of contention include the use of state funds for a drug that is still under FDA development, the safety profile of ibogaine, and whether Texas should invest in a treatment with uncertain federal approval. The bill’s provisions on state commercial interest in intellectual property may also raise questions about public ownership, private profit, and the role of philanthropic or for-profit entities. Additional concerns may involve the requirement to secure coverage from major payors, the need for cardiac-intensive care infrastructure, and the possibility that federal regulatory hurdles could delay or prevent implementation.